FTC Fights Watson's Bid To Block Lidoderm Antitrust Suit
The Federal Trade Commission renewed its opposition Wednesday to Watson Laboratories' bid for a ruling that the agency lacks the authority to pursue a pay-for-delay suit against it over pain relief...To view the full article, register now.
Already a subscriber? Click here to view full article